Table 2: Univariable and Multivariable hazard ratios for clinical factors from the Cox regression analysis for the risk of PSA-failure.

Clinical factorNumber of menNumber of eventsUnivariable analysisMultivariable analysis
HR (95% CI) valueAHR (95% CI) value

Age at diagnosis (years)357340.99 (0.95, 1.04)0.8140.98 (0.92, 1.05)0.542
PSA (ng/mL)357341.09 (1.04, 1.15)0.0011.09 (1.03, 1.16)0.005
PPB (%)357341.04 (1.02, 1.06)<0.0011.03 (1.01, 1.05)0.009
PSA & PPB interaction357340.999 (0.998, 1.000)0.1770.999 (0.998, 1.000)0.054
Highest Gleason score
 620821 (Ref)1 (Ref)
 71211715.24 (3.52, 65.99)<0.0019.70 (2.17, 43.37)0.003
 8–10281567.60 (15.45, 295.75)<0.00125.01 (5.08, 123.14)<0.001
AJCC clinical tumor category
 T1c295191 (Ref)1 (Ref)
 T2-362153.77 (1.91, 7.42)<0.0011.49 (0.72, 3.08)0.283
Type of nerve sparing RP
 BNS18730.043 (0.011, 0.173)<0.0010.407 (0.064, 2.589)0.341
 UNS151250.473 (0.193, 1.156)0.1011.242 (0.355, 4.342)0.734
 Non-NS1961 (Ref) 1 (Ref)

HR: hazard ratio; AHR: adjusted hazard ratio; PSA: prostate-specific antigen; PPB: percentage of positive prostate biopsies; AJCC: American Joint Commission on Cancer; RP: radical prostatectomy; BNS: bilateral nerve sparing; UNS: unilateral nerve sparing; Non-NS: non-nerve sparing.